Manuscripts

The Head Bookworm has edited many manuscripts for journal publication.

Editing includes the following:

Published Articles

Articles that have been published where I have provided editorial assistance:

• Taylor WC, Bui C. Associations between sedentary behaviors and cognitive health in older adults based on the Taylor taxonomy of sedentary behaviors. J Health Psychol. 2026;0(0). doi:10.1177/13591053261419219 (edited; created Figure 1; includes acknowledgement)
• Cornberg M, Zoulim F, Gish R, et al. Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines. Antiviral Therapy. 2025;30(4). doi:10.1177/13596535251349380 (proofed; includes acknowledgement)
• Haddadin R, Molina S, Trad G, Ryan J, Gish R. Evaluating the impact of phosphatidylethanol testing on hospital outcomes. Gastroenterol Res. 2025;17(5-6):205-211. doi:10.14740/gr1790
• Khattak A, Vongsavath T, Haque L, Narwan A, Gish RG. The forgotten virus, hepatitis D: A review of epidemiology, diagnosis, and current treatment strategies. J Clin Exp Hepatol. 2024;14(5):101395. doi: 10.1016/j.jceh.2024.101395 (edited; includes acknowledgement)
• Dossaji Z, Haque L, Khattak A, et al. A review of hepatitis B reactivation risk on immunosuppressants with a focus on newer immunomodulators. Curr Hepatology Rep 2024;23:253–267. doi:10.1007/s11901-024-00662-7 (edited; includes acknowledgement)
• Gish R, Fan JG, Dossaji Z, et al. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Hepatol Int. 2024;18(Suppl 2):977–989. doi:10.1007/s12072-024-10698-y
• Kapoor H, Bi C, Kroll MH, Salm AE, Dominguez EA. Burden and frequency of viral testing of kidney and non-kidney transplant recipients. Microbiol Spectr 2024;12:e03575-23. doi:10.1128/spectrum.03575-23
• Dossaji Z, Haque L, Khattak A, Hsu M, Gish R. A Review of hepatitis B reactivation risk on immunosuppressants with a focus on newer immunomodulators. Curr Hepatology Rep. 2024; 23:253–267. doi:10.1007/s11901-024-00662-7
• Freeland C, Sreepathi V, Hass RW, et al. The importance of triple panel testing for hepatitis B and the burden of isolated anti-hepatitis B core antibodies within a community sample. J Virus Erad. 2023;9(4):100358. doi:10.1016/j.jve.2023.100358 (edited; includes acknowledgement)
• Kroll MH, Bi C, Salm AE, Szymanski J, Goldstein DY, Wolgast LR, Rosenblatt G, Fox AS, Kapoor H. Risk estimation of severe COVID-19 based on initial biomarker assessment across racial and ethnic groups. Arch Pathol Lab Med. 2023;147(10):1109-1118. doi:10.5858/arpa.2023-0039-SA (edited; includes acknowledgement)
• Roma K, Hsu M, Khattak A, et al. Evidence-based strategies for micro-elimination of chronic hepatitis B virus infection. Curr Hepatology Rep. 2023;22:118–129. doi:10.1007/s11901-023-00610-x (edited; includes acknowledgement)
• Roma K, Dossaji Z, Haque L, Laeeq T, Gish RG, Brosgart C. Test all for hepatitis B virus: Link to care and treatment if quantitative DNA positive, vaccinate if susceptible. Clin Liv Dis. 2023;27(4):997-1022. doi:10.1016/j.cld.2023.05.009 (edited; includes acknowledgement)
• Robinson A, Wong R, Gish RG. Chronic hepatitis B virus and hepatitis D virus: New developments. Clin Liver Dis. 2023;27(1):17-25. doi: 10.1016/j.cld.2022.08.001 (edited but no acknowledgement)
• Roma K, Gish RG. Future of chronic hepatitis B infection therapies. Editorial. Gastro Hep Advances 2023;2(4): 556-557. doi:10.1016/j.gastha.2023.02.006 (edited but no acknowledgement)
• Lam D, Wong RJ, Tessier A, Zapata Y, Saldana E, Gish RG. Barriers to hepatitis C virus care and how federally qualified health centers can improve patient access to treatment. Gastroenterology Res. 2022;15(6):343-352. doi:10.14740/gr1568 (edited; includes acknowledgement)
• Pham TND, Le DH, Dao DVB, et al. Establishing baseline framework for hepatitis B virus micro-elimination in Ho Chi Minh City, Vietnam – A community-based seroprevalence study. Lancet Reg Health West Pac. 2022:100620. doi:10.1016/j.lanwpc.2022.100620 (edited; includes acknowledgement)
• Kim TV, Le DH, Dao DVB, et al. Demonstration of a population-based HCV serosurvey in Ho Chi Minh City, Viet Nam: Establishing baseline prevalence of and continuum of care for HCV micro-elimination by 2030. Lancet Reg Health West Pac. 2022;27:100524. doi:10.1016/j.lanwpc.2022.100524 (edited; includes acknowledgement)
• Mesa RA, Sullivan EM, Dubinski D, et al. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey. Cancer. 2022;128(20): 3691-3699. doi:10.1002/cncr.34420 (edited; acknowledgement for Alkemi LLC, with whom I am an Expert Partner)
• Mesa RA, Sullivan EM, Dubinski D, et al. Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey. Cancer. 2022;128(20): 3700-3708. doi:10.1002/cncr.34421 (edited; acknowledgement for Alkemi LLC, with whom I am an Expert Partner)
• Fouad Y, Palmer M, Chen M, et al. Redefinition of fatty liver disease from NAFLD to MAFLD through the lens of drug development and regulatory science. J Clin Translat Hepatol. 2022;10(2):374-382. doi: 10.14218/jcth.2021.00408 (edited; includes acknowledgement)
• Bogliotti Y, Vander Roest M, Mattis AN, Gish RG, Peltz G, Anwyl R, Kivlighn S, Schuur ER. Clinical application of induced hepatocyte-like cells produced from mesenchymal stromal cells: A literature review. Cells. 2022; 11(13):1998. doi:10.3390/cells11131998 (edited; includes acknowledgement)
• Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. Hepatitis C vaccination: where we are and where we need to be. Pathogens. 2021; 10(12):1619. doi:10.3390/pathogens10121619 (edited; includes acknowledgement)
• Nguyen T, Pham T, Tang HK, et al. Unmet needs in occupational health: prevention and management of viral hepatitis in healthcare workers in Ho Chi Minh City, Vietnam: a mixed-methods study. BMJ Open. 2021;11:e052668. doi:10.1136/bmjopen-2021-052668 (edited; includes acknowledgement)
• Zakalashvili M, Zarkua J, Gish RG, Zhamutashvili M, Sartania V, et al. Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. Hepatol Res. 2021;51: 156–165. doi:10.1111/hepr.13587 (edited, includes acknowledgement)
• Gonzalez HC, Imam Z, Wong R, et al. Normal alkaline phosphatase levels are dependent on race/ethnicity: National Health and Nutrition Examination Survey data. BMJ Open Gastro. 2020;7:e000502. doi:10.1136/bmjgast-2020-000502 (edited and submitted, includes acknowledgement)
• Jackson K, Gish RG. Point of care diagnostic testing for Hepatitis B virus. Curr Hepatol Rep. 2020. https://link.springer.com/article/10.1007/s11901-020-00531-z (edited and submitted, includes acknowledgement)
• Clayton NP, Khan-Malek RC, et al. Sargramostim (rhu GM-CSF) improves survival of non-human primates with severe bone marrow suppression after acute, high-dose, whole-body irradiation. Radiat Res. 2020;195(2):191-199. doi: 10.1667/RADE-20-00131.1 (edited; includes acknowledgement as part of Med Communications)
• Underberg JA, Cannon CP, Larrey D, et al. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). J Clin Lipidol. 2020;14(6):807-817. doi:10.1016/j.jacl.2020.08.006 (edited but no acknowledgement)
• Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). MAbs. 2017;9(2):364-382. doi:10.1080/19420862.2016.1264550 (edited, includes acknowledgement)
• Tidwell T, Edwards J, Snider E, et al. A nursing pilot study on bedside reporting to promote best practice and patient/family-centered care. J Neurosci Nurs. 2011;43(4):E1-5.  doi:10.1097/JNN.0b013e3182212a1d (edited but no acknowledgement)